share_log

Cantor Fitzgerald Reiterates Overweight on Mainz Biomed, Maintains $9 Price Target

Benzinga ·  Sep 26, 2023 11:46

Cantor Fitzgerald analyst Ross Osborn reiterates Mainz Biomed (NASDAQ:MYNZ) with a Overweight and maintains $9 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment